HCM
HUTCHMED Achieves Strong First Half Results with 23% Growth in Oncology Revenue
Hutchmed, a leading biopharmaceutical company, has reported strong first half results for 2026. The company's oncology revenue grew by 23%, reaching $162 million, driven by the success of its key products ELUNATE and SULANDA. ELUNATE, Hutchmed's flagship product, saw a remarkable growth rate of over 40%